Radiological and spirometric changes in relation to drugs used in post COVID pulmonary fibrosis in a cohort of COVID-19 survivors

Mohamed Hamoda, Amina Abd El-Maksoud, Aida M. Yousef, Dalia Monir Fahmy, Mohamed Tohlob
{"title":"Radiological and spirometric changes in relation to drugs used in post COVID pulmonary fibrosis in a cohort of COVID-19 survivors","authors":"Mohamed Hamoda, Amina Abd El-Maksoud, Aida M. Yousef, Dalia Monir Fahmy, Mohamed Tohlob","doi":"10.1186/s43168-024-00323-9","DOIUrl":null,"url":null,"abstract":"It has been proposed that prolonged use of anti-inflammatory and anti-fibrotic drugs diminish the probability of development of lung fibrosis. Prolonged low-dose corticosteroid may prevent remodeling of the lung in survivors. Pirfenidone and colchicine may exhibit anti-fibrotic and anti-inflammatory properties as well. This retrospective observational study was conducted at post COVID-19 clinic, Mansoura University Hospitals, during the period between October 2020 and March 2022. This study included 104 patients who had COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and divided into 3 groups; group A (corticosteroids only) included 33 (31.7%) patients, group B (corticosteroids and colchicine) included 56 (53.8%) patients, and group C (corticosteroids, colchicine, and pirfenidone) included 15 (14.4%) patients. All patients were assessed during follow-up visits in post COVID-19 clinic 1 and 3 months after discharge by evaluation of resting SpO2, spirometry, and radiological assessment. Patients’ data during hospitalization was collected from hospital electronic systems. There was non-statistically significant improvement in FEV1 in group A while there was statistically significant improvement in FEV1 in groups B and C (P value = 0.002 and 0.041, respectively) 1 month and 3 months after discharge. Group B exhibited more statistically significant improvement in FVC as well compared to group C (P value = 0.003 and 0.025, respectively) while group A showed non-statistically significant improvement in FVC. There was a statistically significant decrease in CT severity score in all the groups during follow-up with P value < 0.001 in groups A and B and to less extent less statistically significant decrease in group C comparing the 3 groups to each other. The use of colchicine added to corticosteroids after acute phase of COVID-19 pneumonia resulted in statistically significant improvement regarding functional and radiological changes during follow-up when compared to corticosteroids alone. The addition of pirfenidone (which is a relatively expensive drug) to corticosteroids and colchicine did not add more statistically significant improvement in functional or radiological changes.\n","PeriodicalId":22426,"journal":{"name":"The Egyptian Journal of Bronchology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Egyptian Journal of Bronchology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43168-024-00323-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

It has been proposed that prolonged use of anti-inflammatory and anti-fibrotic drugs diminish the probability of development of lung fibrosis. Prolonged low-dose corticosteroid may prevent remodeling of the lung in survivors. Pirfenidone and colchicine may exhibit anti-fibrotic and anti-inflammatory properties as well. This retrospective observational study was conducted at post COVID-19 clinic, Mansoura University Hospitals, during the period between October 2020 and March 2022. This study included 104 patients who had COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and divided into 3 groups; group A (corticosteroids only) included 33 (31.7%) patients, group B (corticosteroids and colchicine) included 56 (53.8%) patients, and group C (corticosteroids, colchicine, and pirfenidone) included 15 (14.4%) patients. All patients were assessed during follow-up visits in post COVID-19 clinic 1 and 3 months after discharge by evaluation of resting SpO2, spirometry, and radiological assessment. Patients’ data during hospitalization was collected from hospital electronic systems. There was non-statistically significant improvement in FEV1 in group A while there was statistically significant improvement in FEV1 in groups B and C (P value = 0.002 and 0.041, respectively) 1 month and 3 months after discharge. Group B exhibited more statistically significant improvement in FVC as well compared to group C (P value = 0.003 and 0.025, respectively) while group A showed non-statistically significant improvement in FVC. There was a statistically significant decrease in CT severity score in all the groups during follow-up with P value < 0.001 in groups A and B and to less extent less statistically significant decrease in group C comparing the 3 groups to each other. The use of colchicine added to corticosteroids after acute phase of COVID-19 pneumonia resulted in statistically significant improvement regarding functional and radiological changes during follow-up when compared to corticosteroids alone. The addition of pirfenidone (which is a relatively expensive drug) to corticosteroids and colchicine did not add more statistically significant improvement in functional or radiological changes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19幸存者组群的放射学和肺活量变化与COVID后肺纤维化所用药物的关系
有研究认为,长期服用抗炎和抗纤维化药物可降低肺纤维化发生的概率。长期服用小剂量皮质类固醇可防止幸存者肺部重塑。吡非尼酮和秋水仙碱也可能具有抗纤维化和抗炎作用。这项回顾性观察研究于 2020 年 10 月至 2022 年 3 月期间在曼苏尔大学医院 COVID-19 后诊所进行。该研究纳入了 104 名经 RT-PCR 或 CT 扫描放射学证实患有 COVID-19 肺炎的患者,并将其分为 3 组:A 组(仅皮质类固醇)包括 33 名(31.7%)患者,B 组(皮质类固醇和秋水仙碱)包括 56 名(53.8%)患者,C 组(皮质类固醇、秋水仙碱和吡非尼酮)包括 15 名(14.4%)患者。所有患者均在出院后 1 个月和 3 个月在 COVID-19 后诊所接受随访,评估静息 SpO2、肺活量和放射学评估。患者住院期间的数据由医院电子系统收集。A 组患者的 FEV1 改善无统计学意义,而 B 组和 C 组患者出院 1 个月和 3 个月后的 FEV1 改善有统计学意义(P 值分别为 0.002 和 0.041)。与 C 组相比,B 组在 FVC 方面的改善更具有统计学意义(P 值分别为 0.003 和 0.025),而 A 组在 FVC 方面的改善无统计学意义。在随访期间,A 组和 B 组的 CT 严重程度评分均有统计学意义上的明显降低,P 值均小于 0.001,而 C 组的 CT 严重程度评分的下降幅度较小,三组间比较无统计学意义。与单独使用皮质类固醇相比,COVID-19 肺炎急性期后在使用皮质类固醇的基础上加用秋水仙碱,可在随访期间明显改善功能和放射学变化。在皮质类固醇和秋水仙碱的基础上添加吡非尼酮(一种相对昂贵的药物),并没有在功能和放射学变化方面带来更多统计学意义上的明显改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Severity, mortality, and incidence of venous thromboembolism in COVID-19 patients Accuracy of convex probe EBUS-TBNA versus FDG-PET/CT imaging in diagnosis and mediastinal staging of lung cancer patients; an Egyptian Experience Role of pleural manometry and transthoracic ultrasonography to predict entrapped lung Comparing the outcome of using high-flow nasal cannula oxygen therapy versus noninvasive ventilation for chronic obstructive pulmonary disease patients with acute hypercapnic respiratory failure The role of screening of patients proved to have gastroesophageal reflux disease by upper gastrointestinal endoscope for early detection of interstitial lung diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1